Axcelis Technologies, Inc. (NASDAQ:ACLS) recorded a trading volume of 0.75 million shares, above its 90-day volume average of 0.63 million shares. The stock kicked off the session at $35.05 and later approached $36.6 with a change of 4.57%.Axcelis Technologies, Inc. (ACLS) Analyst Opinion
Axcelis Technologies, Inc. has a consensus outperform rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 5.82% of shares outstanding. The stock spiked 10.57% last month and is up 151.55 this year. Wall Street is only getting more bullish on the stock, with 3 of analysts who cover ACLS having a buy-equivalent rating. Analysts have placed a $35.2 price target on Axcelis Technologies, Inc., suggesting a -3.83% decline from recent close. It’s currently trading about 1.1% above its 52-week high.
Axcelis Technologies, Inc. (ACLS) surprised the stock market in its last reported earnings when it earned $0.38 a piece versus the consensus-estimated $0.28. Its revenue totaled $95.1 million down -7.48% from the previous quarter.Axcelis Technologies, Inc. (NASDAQ:ACLS) Intraday View
This stock (ACLS) is ahead of its 52-week low with 189.33%. Its last month’s stock price volatility remained 3.14% which for the week stands at 4.07%. The share price has moved forward from its 20 days moving average, trading at a distance of 9.22% and stays 22.63% away from its 50 days moving average. Over the last five days, shares have managed 5.48% gains and now is up 63.43% since hitting its 200-day moving average of $24.78. Axcelis Technologies, Inc. (ACLS) has made its way to a 12-month gain of 163.31%.
Turning to Clovis Oncology, Inc. (NASDAQ:CLVS), its shares were trading at $61.17 a retreat of $-2.71, on the trading floor. The stock, after opening at $64, touched a high of $64.06 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Clovis Oncology, Inc. has 4 buy ratings, 4 holds and 0 sells even after the stock tumbled -38.49% from its high of $99.45 to a $3.17 billion market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $91.17 a share. The target implies a 49.04% spike from where the shares are currently trading. Also, the current price highlights a discount of 104.35% to analysts’ high consensus price target.Clovis Oncology, Inc. (NASDAQ:CLVS) Intraday Trading
The counter witnessed a trading volume of 1.23 million shares versus an average volume of 1.41 million shares during last trading session. Its last month’s stock price volatility remained 4.63% which for the week approaches 4.52%. The lowest price the stock reached in the last trading day was $60.8 and compares with the $33.23 52-week low. The stock recovered 84.08% since its low point and has performed 37.71% year-to-date.